Anti-venom Market Explore Future Growth 2018-2026 by Global Top Players – Haffkine Bio-Pharmaceutical Corporation, Bharat Serums and Vaccines, Vins Bioproducts, CSL Behring, Vacsera, Rare Therapeutics, Instituto Bioclon S.A.de C.V., Incepta Vaccine

Coherent Market Insights has announced the addition of the “Anti-venom Market Size Status and Forecast 2026”, The report classifies the global Anti-venom in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

This report studies the global Anti-venom Speaker market, analyzes and researches the Anti-venom Speaker development status and forecast in North America, Europe, Asia Pacific, Latin America and Rest of the World. This report focuses on the top players in global market, like Haffkine Bio-Pharmaceutical Corporation, Bharat Serums and Vaccines, Vins Bioproducts, CSL Behring, Vacsera, Rare Therapeutics, Instituto Bioclon S.A.de C.V., Incepta Vaccine

Request a sample copy : https://www.coherentmarketinsights.com/insight/request-sample/1249

Growth of the anti-venom market is expected to be driven by South Asia and sub-Saharan African countries due to highest incidence of snake bites in these regions. As per WHO statistics, in India, 3.8 million people are bitten by snakes and 46,900 people die every year. In sub-Saharan Africa, around 7,000 to 20,000 people die annually from snake bites. Highest incidence is recorded in rural and peri-urban areas, where croppers and livestock workers live. However, growing urbanization is resulting in the loss of habitat for many snake species due to deforestation, thus drawing them towards area inhabited by humans, in turn, increasing the incidence of snakebites. The WHO, in June 2017, added snakebite to its priority list of neglected tropical disease, which would result in more focused effort to prevent death from snakebite, thus boosting growth of the anti-venom market. Increasing government funding for research and development and logistics in these countries is further drive growth of the global anti-venom market.

Anti-venom is a medication majorly used to treat snake bites and it can also be used to treat bites from scorpions, spiders or other reptiles. It is made by fractionating the blood of the donor (horse or sheep), which is hyper immunized with snake venom. These products are available in either lyophilized or liquid forms. Anti-venom is the only effective therapy against snake bites and apart from lifesaving, they also save patients from cell and tissue necrosis, thus helping save vital organs. As per World Health Organization (WHO) fact sheet, 4.5 to 5.4 million people are bitten by snakes, every year, globally, out of which 1.8 to 2.7 million people develop clinical illnesses after snake bites and up to 81,000 to 1, 38,000 people die from such snake bites. Snake bite causes around 400,000 amputations and other permanent disabilities, annually.

According to WHO, most of the sub-Saharan African region does not locally produce anti-venom, thus the populace in this region relies on traditional treatment to treat snakebites. Countries in this region often face chronic shortage of anti-venom production, thus, creating opportunities for market players to enter the anti-venom market. Presently, the available anti-venom product is not effective against snake bites from certain species such as hump-nosed vipers (India) and other species present in African counties. This in turn, is limiting market expansion.

On the basis of anti-venom type:

Monovalent (Hyper immunizing venom obtained from single species)
Polyvalent (Hyper immunizing venom from two or more species)

On the basis of product type:

Snake anti-venom
Scorpion anti-venom
Spider anti-venom
Other anti-venom products

On the basis of distribution channel:

Hospitals
Private clinics
Ambulatory surgical centers

Ongoing research in the anti-venom products market is increasing the scope for market growth. Venomab is a company focusing on production of anti-venom, by using humanized antibodies instead of traditional serum-based animal derived anti-venom. This in turn, would reduce cost and scale up the production, alongside would improve availability of the products.

The anti-venom market is dominated mostly by the producers from emerging economies such as India, Brazil, and Mexico. In 2014, Sanofi Pasteur announced that it would not produce its anti-venom product Fav-Afrique (mostly sold in African countries), which is one of the most effective polyvalent anti-venom products. This was due to tough competition from low cost manufacturers from emerging economies such as India, Brazil, and Mexico.

Else place an Inquire before Purchase “Anti-venom Market Size, Status and Forecast 2026 : https://www.coherentmarketinsights.com/insight/talk-to-analyst/1249

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.